Skin & hair · Cream

SNAP-8

Gray market

Checked 18 Oct 2026 · 21 sources · 10 corrections on this page · No vendors · No affiliates · No one buys a word of it

0 independent trials published

Limited Evidence · its maker’s own work

Gray market · No FDA ruling — not on any list

Sold as a cosmetic ingredient in creams and serums.

Bottom line

Same story as Argireline, two extra amino acids, no independent trial of its own.

Also called: Acetyl Octapeptide-3 (INCI)
Acetyl Glutamyl Heptapeptide-1
SNAP-8™ (Lipotec trade)
"Botox-like" topical peptide
Category: Peptide — Topical Cosmetic / SNARE-Complex Mimetic
Molecular Weight: 1,075.2 g/mol (acetyl octapeptide-3)
Sequence: 8 amino acids
(Ac-EEMQRRAD-NH₂)
Target: SNAP-25 / SNARE complex
Route (studied): Topical (people)
Route (sold): Topical creams and serums (cosmetic); vials (lab reagent)
Developer: Lipotec (Grupo LUBRIZOL)
Use Concentration: 3–10% in formulation
FDA Status: Cosmetic ingredient only
Clinical Evidence: In vitro + manufacturer
in-vivo cosmetic studies
WADA Status: Not listed
Cost & Access: Research-only

Also for skin & hair

The other four questions

What does it do? Relaxes expression lines the same way Argireline does. Blocks the same signaling protein (SNAP-25) that Botox blocks, by mimicking a fragment of it. Its maker reports that it blocks SNARE assembly in cell assays (Lipotec product documentation); whether that happens in skin has not been shown independently.
Who uses it? Cosmetic formulators at 3–10% in eye creams and anti-expression-line serums.
Does the evidence hold up? Thin. Lipotec's own in-vitro and consumer-perception studies only. No independent peer-reviewed human trials. Even Argireline has more published evidence than this one.
Bottom line? Same story as Argireline, two extra amino acids, no independent trial of its own.

Dosing from the Literature

Published for wrinkles: the maker's 3–10% in creams, twice a day. Not published: an independent trial at any strength.

SNAP-8 dosing is entirely within the cosmetic-topical paradigm. No injected or oral dose exists in published literature:

Context	Concentration / Dose	Route	Notes
Manufacturer recommended cosmetic use	3–10% in finished formulation	Topical twice daily	Lipotec recommended range for anti-wrinkle serums, creams, and eye products.
Lipotec in-vivo 28-day study	4% in vehicle	Topical twice daily × 28 days	Vehicle was aqueous cosmetic emulsion; penetration enhanced with glycerin/propylene glycol.
High-concentration consumer serums	Up to 10%	Topical twice daily	Higher concentrations used in premium anti-aging skincare products.

Dosing Disclaimer

SNAP-8 is a topical cosmetic ingredient. The only legitimate use route is topical application at 3–10% concentration in cosmetic formulations, twice daily. Injected or oral SNAP-8 has no published safety or efficacy data, no pharmacological rationale at community doses, and no place in community peptide protocols. Consumer framing of SNAP-8 as a "botox injection alternative" refers to topical application, not to injection of SNAP-8 itself.

What It Is

SNAP-8 is a synthetic 8-amino-acid peptide with the sequence Ac-Glu-Glu-Met-Gln-Arg-Arg-Ala-Asp-NH₂ (one-letter code Ac-EEMQRRAD-NH₂). The N-terminus is acetylated and the C-terminus is amidated — modifications that stabilize the peptide against aminopeptidase and carboxypeptidase degradation and improve formulation stability in topical products. Molecular weight is approximately 1,075 Da.

The INCI (International Nomenclature of Cosmetic Ingredients) name is Acetyl Octapeptide-3. An alternative name occasionally used is Acetyl Glutamyl Heptapeptide-1. The trade name SNAP-8™ is held by Lipotec (Spain), now part of Grupo LUBRIZOL. SNAP-8 was developed as a next-generation cosmetic active following Lipotec's earlier peptide Argireline® (Acetyl Hexapeptide-8, Ac-Glu-Glu-Met-Gln-Arg-Arg-NH₂), sharing Argireline's first six amino acids plus an additional Ala-Asp C-terminal extension designed to improve receptor-mimetic affinity and wrinkle-reduction efficacy.

SNAP-8's design intent is to mimic the N-terminal region of SNAP-25 (Synaptosomal-Associated Protein, 25 kDa), a presynaptic membrane protein that forms part of the SNARE (the machinery that releases neurotransmitters) complex (together with syntaxin-1 and VAMP/synaptobrevin) essential for synaptic vesicle fusion and neurotransmitter release at the neuromuscular junction. Botulinum toxin type A, the pharmacological active in Botox®, cleaves SNAP-25 at a specific site to destroy SNARE-complex formation and paralyze the affected muscle. SNAP-8 approaches the same SNARE machinery through a competitive inhibition rather than proteolytic destruction — binding the SNARE-forming partners at a mimetic site rather than destroying SNAP-25 — producing a reversible, dose-dependent attenuation of SNARE assembly rather than the long-lasting paralysis of botulinum toxin.

SNAP-8 is supplied as a synthetic peptide by Lipotec and is incorporated into topical cosmetic formulations at 3–10% concentration by multiple downstream skincare manufacturers. It also exists in research-reagent channels for in-vitro SNARE-complex research. There is no FDA-approved SNAP-8 drug product, no investigational therapeutic program, and no human clinical trial in the pharmaceutical-development sense — SNAP-8 occupies the cosmetic-ingredient regulatory pathway rather than the pharmaceutical one.

Mechanism of Action

SNAP-8's mechanism is narrowly defined as a SNARE-complex competitive inhibitor. Unlike most peptides on this site, its pharmacological target is a specific intracellular protein-protein interaction:

SNARE complex basics — Neurotransmitter release at the neuromuscular junction and other synapses requires docking and fusion of neurotransmitter-containing synaptic vesicles with the presynaptic membrane. This fusion is driven by the SNARE complex — a four-helix bundle formed by SNAP-25 (two helices), syntaxin-1 (one helix), and VAMP/synaptobrevin (one helix). Calcium influx through voltage-gated Ca²⁺ channels during the action potential binds synaptotagmin, which then catalyzes the SNARE-mediated fusion event. SNARE complex formation is the rate-limiting molecular step in neurotransmitter release.
SNAP-25 N-terminus mimicry — SNAP-8's sequence corresponds to the N-terminal region of SNAP-25. In competitive in-vitro SNARE-complex assembly assays, SNAP-8 occupies a binding site on the partner SNARE proteins, preventing endogenous SNAP-25 from engaging productively. Reduced SNARE complex formation → reduced vesicle fusion → reduced acetylcholine release at the neuromuscular junction → attenuated muscle contraction.
Competitive rather than proteolytic — The mechanism is reversible. Unlike botulinum toxin, which irreversibly cleaves SNAP-25 via its protease activity, SNAP-8's competitive binding is displaced when SNAP-8 dissociates or is degraded, allowing normal SNARE assembly to resume. This gives SNAP-8 a theoretically more controllable pharmacological profile but also a substantially weaker effect size than proteolytic botulinum toxin.
Reduced neurotransmitter release → attenuated muscle contraction — In cell-culture models of neuromuscular junction preparations, SNAP-8 reduces evoked acetylcholine release. Translated to cosmetic application, the claim is reduced contraction of small facial expression muscles (procerus, corrugator supercilii, orbicularis oculi) that drive dynamic wrinkles like glabellar lines and crow's feet.
Topical penetration — As a hydrophilic 8-mer of about 1,075 Da, SNAP-8 sits at the upper edge of the conventional ~500 Da molecular-weight ceiling for passive stratum corneum penetration. Topical formulation typically uses penetration-enhancing vehicles (liposomes, lipid nanoparticles, glycerin/propylene glycol) to support adequate dermal delivery. Pintea et al. 2023 and others have studied controlled-release nanoparticle delivery to increase efficiency.
No systemic bioavailability — From topical application at cosmetic concentrations, systemic absorption of intact SNAP-8 is minimal to undetectable. The mechanism is restricted to local dermal / neuromuscular effects at the application site. This is an important safety feature — it limits the risk of systemic SNARE inhibition that could theoretically affect off-target neuromuscular junctions.
Comparison to Argireline — The maker reports side-by-side studies in which SNAP-8 reduced wrinkle depth about 30% more than Argireline at the same concentration (Lipotec product documentation). No independent study has compared the two.
Reversibility and half-life — Topical SNAP-8 effect is transient (hours to days); twice-daily topical application is the standard cosmetic protocol to maintain effect. There is no long-term "accumulation" mechanism.

What the Research Shows

SNAP-8 has a narrow published evidence base, entirely within the cosmetic-ingredient research paradigm rather than pharmaceutical drug development:

Lipotec manufacturer in-vitro studies — Original in-vitro SNARE-complex assembly assays demonstrated competitive inhibition by SNAP-8, with IC50 values in the micromolar range. These studies form the mechanistic foundation for cosmetic marketing but were not peer-reviewed independent pharmacological characterization.
Manufacturer in-vivo cosmetic studies — Lipotec-sponsored in-vivo studies reported ~21% wrinkle-smoothing and 15–20% wrinkle-depth reduction at 4% SNAP-8 over 28 days, with wrinkle-smoothing evident in 80% of subjects and wrinkle reduction in 73%. Maximum reported reduction ~52% in selected subjects. These are cosmetic-industry consumer-perception and image-analysis studies, not pharmaceutical Phase 2 / 3 trials.
Jung JH et al. Journal of Analytical Science and Technology 2020 — Method development paper for acetyl octapeptide-3 analysis by liquid chromatography–tandem mass spectrometry. Primarily analytical rather than pharmacodynamic, but establishes quantification methodology for regulatory and formulation work.
Computational / molecular modeling studies — Pintea et al. and others have published molecular dynamics and docking studies characterizing SNAP-8 binding to the SNARE complex and to synaptotagmin, supporting the mechanistic hypothesis without providing independent in-vivo efficacy confirmation.
Nanoparticle delivery studies — Several formulation-chemistry papers have explored nanoparticle-encapsulated SNAP-8 as a controlled-release delivery strategy to enhance dermal penetration and residence time. These are formulation-optimization studies rather than efficacy trials.
No independent head-to-head trials with botulinum toxin — No peer-reviewed independent study has directly compared topical SNAP-8 to injected botulinum toxin A. Manufacturer and marketing materials present favorable comparisons, but these are framed as alternative modalities rather than demonstrated therapeutic equivalents. Clinically, injected botulinum toxin at typical aesthetic doses produces substantially greater and longer-lasting wrinkle reduction than topical SNAP-8 ever can.
No pharmaceutical Phase 1/2/3 trials — SNAP-8 has no IND and no clinical-trials.gov registered protocols. It exists exclusively in the cosmetic-ingredient regulatory pathway.

Critical Context — "Botox-Alternative" Marketing Overstates Effect Size

No study has compared topical SNAP-8 with injected botulinum toxin (see above). The two differ in route and in mechanism: botulinum toxin A is injected and cuts SNAP-25 with its protease activity, while SNAP-8 is described as binding competitively and reversibly (Montal, 2010; Dressler & Benecke, 2007). What its maker’s own 28-day study reported for a 4% cream is above: about 21% wrinkle smoothing and 15–20% less wrinkle depth.

Human Data

SNAP-8 human data is exclusively from manufacturer-sponsored cosmetic-industry in-vivo studies and consumer-perception research. There are no pharmaceutical clinical trials.

Manufacturer in-vivo studies — Lipotec in-vivo studies on volunteers using 4% SNAP-8 in cosmetic emulsion over 28 days report:
- • 21% skin-smoothing improvement vs baseline
- • 15–20% wrinkle-depth reduction vs baseline
- • Maximum wrinkle-depth reduction 52% in selected responders
- • Effect measurable in ~80% of volunteers
- • Wrinkle-reduction effect in ~73% of volunteers
Manufacturer comparison to Argireline — Side-by-side in-vivo studies report SNAP-8 ~30% more effective than equivalent concentration of Argireline (Acetyl Hexapeptide-8) for wrinkle-depth reduction, supporting the "next-generation" marketing claim.
Independent peer-reviewed human trials — None published. The Jung 2020 method-development paper and computational modeling studies do not constitute efficacy evidence.
Consumer-perception surveys — Large-scale consumer surveys through cosmetic-industry channels report generally favorable user satisfaction, but these are consumer ratings rather than controlled clinical outcome measures.
No injection trials — No injected SNAP-8 trial has been conducted in humans for any indication. There is no pharmacological rationale for injection (systemic SNARE inhibition is neither achievable nor desirable at community doses), and no safety data supports injection use.
Pediatric / pregnancy data — No specific pediatric or pregnancy trials.

Reconstitution & Storage

SNAP-8 reaches people in finished cosmetic products; formulators and laboratories buy it as raw peptide. No document read for this page gives storage conditions, a shelf life or stability data for any of those forms.

Side Effects & Risks

Important

What is published about SNAP-8 is its maker’s own work: SNARE-assembly assays in cells and a 28-day study of a 4% cream in volunteers, with no independent trial and no registered trial of it at all (Lipotec product documentation; ClinicalTrials.gov, searched October 11, 2026). No study has measured whether it reaches anything below the skin. Consult a licensed healthcare provider.

Its maker’s documentation reports no safety problem in that study; what the published reports describe is skin tolerance, nothing measured inside the body (Lipotec product documentation):

Mild topical reactions — Occasional redness, itching, or irritation at application sites, typically related to other formulation components (preservatives, fragrance) rather than SNAP-8 itself. Self-limiting.
Rare hypersensitivity — As a synthetic peptide, hypersensitivity reactions are uncommon but possible.
No systemic effects at topical cosmetic doses — Systemic absorption is minimal; no documented systemic neuromuscular effects from topical cosmetic use at 3–10% concentration.
Pregnancy and children — No study in either appears in the documents read for this page.
Drug interactions — None has been studied.
Injection — No published study has injected SNAP-8 into a person, and no document read for this page describes such use.

Bloodwork & Monitoring

No trial, label or guideline sets monitoring for SNAP-8, and its published studies are its maker’s own cosmetic assessments over 28 days (Lipotec product documentation).

Commonly Stacked With

No published study has combined SNAP-8 with another compound. Its maker reports side-by-side comparisons with Argireline, not combinations (Lipotec product documentation).

Stacking this? Read the receipt →

→ Calculator — vial-to-syringe math

Legal Status

Current Status — October 2026

SNAP-8 (Acetyl Octapeptide-3) is sold as a cosmetic ingredient, not a pharmaceutical. The EU’s cosmetic ingredient database lists Acetyl Octapeptide-3 (CosIng, read October 11, 2026), and in the United States cosmetics carrying it fall under the Modernization of Cosmetics Regulation Act of 2022 (FDA).

SNAP-8 is not an FDA-approved drug for any indication, and no trial of it is registered (ClinicalTrials.gov, searched October 11, 2026).

SNAP-8 is not on the FDA Category 2 Bulk Drug Substances list, and it was not among the 12 peptides FDA removed from that list in April 2026 (FDA 503A categories list, April 22, 2026). The peptide compounding framework does not apply to cosmetic ingredients. U.S. compounding pharmacies cannot legally compound SNAP-8 as a pharmaceutical; the legitimate supply pathway is through cosmetic-ingredient channels to finished-product manufacturers.

SNAP-8 is not specifically named on the WADA Prohibited List. It is sold as a cosmetic, not as a therapeutic product (WADA Prohibited List 2026).

Cost & Access

SNAP-8 is not approved for human use as a pharmaceutical. It is available through research suppliers for laboratory research purposes only, and through cosmetic-ingredient supply chains to finished-product skincare manufacturers.

Consumer access to SNAP-8 is through finished cosmetic products — anti-aging serums, creams, and eye products marketed by multiple skincare brands. These are legal consumer cosmetics, not pharmaceutical products, and operate under cosmetic-regulation frameworks in their respective jurisdictions.

U.S. compounding pharmacies cannot legally compound SNAP-8 as a pharmaceutical under current FDA rules — it has no FDA-approved pharmaceutical reference product and is not a recognized 503A bulk ingredient. Research-reagent vendors supply synthetic peptide for laboratory use at variable purity and pricing.

SNAP-8 was not among the 12 peptides FDA removed from Category 2 in April 2026 (FDA 503A categories list, April 22, 2026). As a cosmetic ingredient rather than a peptide drug candidate, it falls outside the pharmaceutical compounding framework entirely.

Estimated pricing as of April 2026. Actual costs vary by provider, location, and prescription status. Kalios does not sell compounds.

Next Steps

→ Compare with Argireline — the six-residue original →

→ Calculator — vial-to-syringe math →

→ Every Skin & hair compound →

References

Lipotec S.A. / Grupo LUBRIZOL. SNAP-8™ (Acetyl Octapeptide-3) product documentation and in-vivo manufacturer studies. (Foundational in-vitro SNARE-complex characterization and 4% / 28-day in-vivo cosmetic efficacy data — industry sponsor documentation.)
Jung JH, Ji JY, Kim JW, Kim DY, Lim HJ, Lee HS, Jin JS, Kim YS. Method development for acetyl octapeptide-3 analysis by liquid chromatography-tandem mass spectrometry. J Analytical Sci Technol. 2020;11(1):25. (Analytical method development for quantifying SNAP-8 in cosmetic formulations.)
Pintea A, Manea A, Pintea C, Vlad RA, Bîrsan M, Antonoaea P, Rédai EM, Ciurba A. New insight into anti-wrinkle treatment: Using nanoparticles as a controlled release system to increase acetyl octapeptide-3 efficiency. (Nanoparticle-delivery optimization study.)
Molecular modeling elucidates the cellular mechanism of synaptotagmin-SNARE inhibition: a novel plausible route to anti-wrinkle activity of botox-like cosmetic active molecules. (Computational binding characterization.)
Sudhof TC, Rothman JE. Membrane fusion: grappling with SNARE and SM proteins. Science. 2009;323(5913):474-477. PMID: 19164740. (Foundational SNARE-complex biology — Nobel Prize context for the mechanism SNAP-8 targets.)
Jahn R, Fasshauer D. Molecular machines governing exocytosis of synaptic vesicles. Nature. 2012;490(7419):201-207. PMID: 23060190. (SNARE-complex mechanistic review.)
Blanes-Mira C, Clemente J, Jodas G, Gil A, Fernández-Ballester G, Ponsati B, Gutierrez L, Pérez-Payá E, Ferrer-Montiel A. A synthetic hexapeptide (Argireline) with antiwrinkle activity. Int J Cosmet Sci. 2002;24(5):303-310. PMID: 18498523. (Argireline characterization — direct predecessor to SNAP-8.)
Wang Y, Wang M, Xiao XS, Huo J, Zhang WD. The anti-wrinkle efficacy of Argireline. J Cosmet Laser Ther. 2013;15(4):237-241. PMID: 23464592. (Argireline efficacy data providing comparator context for SNAP-8.)
Dong L, Liu W, Bai X, et al. Molecular modelling of synaptotagmin-SNARE protein-protein interactions and implications for rational SNARE-targeted peptide design. (Computational anti-wrinkle peptide mechanistic study.)
Montal M. Botulinum neurotoxin: a marvel of protein design. Annu Rev Biochem. 2010;79:591-617. PMID: 20233039. (Botulinum toxin / SNAP-25 mechanism — comparator framework for SNAP-8.)
Dressler D, Benecke R. Pharmacology of therapeutic botulinum toxin preparations. Disabil Rehabil. 2007;29(23):1761-1768. PMID: 18033601. (Injected botulinum toxin clinical pharmacology — comparator for SNAP-8 topical claims.)
Draelos ZD. Cosmeceuticals: topical anti-aging products. Postgrad Med. 2007;119(1):66-73. (Cosmetic anti-aging peptides review.)
Resende DISP, Ferreira M, Magalhães C, Sousa Lobo JM, Sousa E, Almeida IF. Trends in the use of marine ingredients in anti-aging cosmetics. Algal Res. 2021;55:102273. DOI: 10.1016/j.algal.2021.102273. (Cosmetic peptide landscape context.)
Ruiz MA, Clares B, Morales ME, Cazalla S, Gallardo V. Preparation and stability of cosmetic formulations with an anti-aging peptide. J Cosmet Sci. 2007;58(2):157-171. PMID: 17520155. (Cosmetic formulation chemistry for peptide actives.)
Zhang Y, Xu Q, Zhuang C. Synthesis and preliminary evaluation of the anti-wrinkle effect of acetyl octapeptide-3 (SNAP-8). Chin J Dermatol. 2016;49(8):593-596. (Chinese dermatology journal report on SNAP-8 — one of the few peer-reviewed non-manufacturer SNAP-8 studies.)
European Commission Cosmetic Ingredient Database (CosIng). Acetyl Octapeptide-3. ec.europa.eu. (EU cosmetic-ingredient regulatory listing.)
Personal Care Products Council INCI Dictionary. Acetyl Octapeptide-3. (INCI nomenclature and standard cosmetic-ingredient classification.)
FDA. Modernization of Cosmetics Regulation Act (MoCRA). fda.gov. 2022. (U.S. cosmetic-regulation framework applicable to SNAP-8-containing products.)
EC Cosmetic Products Regulation 1223/2009. (EU cosmetic-regulation framework.)
PubChem CID 60210007. Acetyl octapeptide-3 (SNAP-8). (Structural and physicochemical reference.)
FDA. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the FD&C Act (503A categories list), versions updated April 15, April 22 and May 14, 2026. fda.gov/media/94155/download. Read October 3, 2026. (Notice that 12 peptides would leave Category 2 because their nominations were withdrawn; their removal; GHK-Cu, except injectable, back in Category 1.)